Form 4: Vaxcyte Executive Sells Shares Under 10b5-1 Plan

Vaxcyte's SVP of Finance and CAO, Elvia Cowan, sold 1,892 shares of common stock on March 17, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Elvia Cowan, SVP, Finance & CAO of Vaxcyte, Inc. (PCVX), reported sales of common stock.
• A total of 1,892 shares were sold in two separate transactions on March 17, 2026.
• The first transaction involved the sale of 1,487 shares at a weighted-average price of $55.387 per share, with prices ranging from $54.98 to $55.935.
• The second transaction involved the sale of 405 shares at a weighted-average price of $56.263 per share, with prices ranging from $56.00 to $56.42.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
• Following these transactions, Elvia Cowan beneficially owns 28,975 shares of Vaxcyte common stock.
• No other shares subject to a Lock-Up Agreement dated January 29, 2026, were sold by the reporting person.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, which typically has a neutral impact on market sentiment as it does not suggest new information about the company's performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a pre-arranged Rule 10b5-1 trading plan are a common practice for corporate executives to diversify holdings and manage liquidity. Such planned sales are generally viewed as less indicative of management's sentiment regarding the company's future prospects compared to unplanned, open-market sales.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by an executive under a pre-arranged plan is unlikely to have a significant direct impact on existing shareholders, as it is a routine event.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled insider sale under a 10b5-1 plan, which is a routine event and does not typically signal a change in company fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Vaxcyte, PCVX, Insider Transaction, Stock Sale, 10b5-1 Plan, Elvia Cowan, SVP Finance, CAO